Key facts
- It has raised $5.8M.
- Notable investors include Creative Destruction Lab, Endless Frontier Labs, Blue Horizon Corporation, Noordelijke Ontwikkelings Maatschappij, RUG Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for EV Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for EV Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EV Biotech
Developer of microbial production strains designed to predict optimal strain modifications, growth media supplementation and optimization. The company solves the issue of pollution-heavy manufacturing methods by harnessing the power of fermentation combined with computational methods and leverages microbiology, genetic engineering and system biology to develop chemical compounds, enabling industrial clients to meet desired and personalized biochemical requirements.
- Sector
- Healthcare
- HQ
- Groningen, Netherlands
- Founded
- 2018
- Employees
- 14
- Website
- evbio.tech/
- Ownership
- Privately Held (backing)
EV Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EV Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EV Biotech in its N-PORT filings yet. We sweep new filings monthly.